PRESS-RELEASE filed Aug 6, 2026 at 08:15 ET
CG Oncology reported Q2 2026 EPS of -$0.90, significantly wider than the consensus estimate of -$0.64 (a 40.6% miss), with revenue of $1.157M (vs consensus $363K, a 218.7% beat). The net loss widened to $79.1M from $41.4M a year ago, driven by a 74% increase in R&D spend and a 66% increase in G&A costs. The stock is likely to be pressured by the EPS miss and the concurrent $500M ATM equity offering, which signals aggressive funding needs and potential dilution, partially offset by the revenue beat and positive pipeline milestones (PIVOT-006 topline data expected soon, BLA submission in Q4 2026). The company has $1.0B in cash, sufficient through 2029, but the massive capital raise overshadows the near-term outlook.